Skip to main content
Journal cover image

Preliminary Gastrointestinal Safety and Tolerability of Fedratinib from the Phase IIIb FREEDOM Trial in Patients with Intermediate- or High-Risk Myelofibrosis Previously Treated with Ruxolitinib

Publication ,  Conference
Gupta, V; Yacoub, A; Fazal, S; Miller, C; Verstovsek, S; Mesa, R; Harrison, C; Barosi, G; Kiladjian, J-J; Mattison, R; Rein, L; Reeves, B ...
Published in: CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
2020

Duke Scholars

Published In

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA

EISSN

2152-2669

ISSN

2152-2650

Publication Date

2020

Volume

20

Start / End Page

S331 / S332

Related Subject Headings

  • 3211 Oncology and carcinogenesis
  • 3201 Cardiovascular medicine and haematology
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Gupta, V., Yacoub, A., Fazal, S., Miller, C., Verstovsek, S., Mesa, R., … Talpaz, M. (2020). Preliminary Gastrointestinal Safety and Tolerability of Fedratinib from the Phase IIIb FREEDOM Trial in Patients with Intermediate- or High-Risk Myelofibrosis Previously Treated with Ruxolitinib. In CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (Vol. 20, pp. S331–S332).
Gupta, Vikas, Abdulraheem Yacoub, Salman Fazal, Carole Miller, Srdan Verstovsek, Ruben Mesa, Claire Harrison, et al. “Preliminary Gastrointestinal Safety and Tolerability of Fedratinib from the Phase IIIb FREEDOM Trial in Patients with Intermediate- or High-Risk Myelofibrosis Previously Treated with Ruxolitinib.” In CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 20:S331–32, 2020.
Gupta V, Yacoub A, Fazal S, Miller C, Verstovsek S, Mesa R, Harrison C, Barosi G, Kiladjian J-J, Mattison R, Rein L, Reeves B, Oh S, Parameswaran V, Deeg J, Rose S, Chia V, Wang T, Talpaz M. Preliminary Gastrointestinal Safety and Tolerability of Fedratinib from the Phase IIIb FREEDOM Trial in Patients with Intermediate- or High-Risk Myelofibrosis Previously Treated with Ruxolitinib. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2020. p. S331–S332.
Journal cover image

Published In

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA

EISSN

2152-2669

ISSN

2152-2650

Publication Date

2020

Volume

20

Start / End Page

S331 / S332

Related Subject Headings

  • 3211 Oncology and carcinogenesis
  • 3201 Cardiovascular medicine and haematology
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences